Resources

September has got off to a busy start at BIA, with significant raises, deals, expansion and M&A activity for members; welcoming our US counterparts to London, closely monitoring UK political shuffles and the party conference action as that kicks off with Reform and some unwelcome anti-vaccine misinformation.

NRG Therapeutics Ltd. (“NRG”), an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is delighted to announce the closing of its oversubscribed £50m Series B financing.

In this blog, Paul Nelson, Corporate Foreign Exchange at Moneycorp, outlines the unpredictability of global markets and what this means for BIA members. 

Pharmaron is thrilled to announce the successful completion of Phase One in the major expansion of our Liverpool Gene Therapy and Biologics CDMO site!

MultiOmic Health Limited (“MOH”), an artificial intelligence (AI)-enabled precision medicine biotechnology company, and BIO4 Campus (“BIO4”), the Republic of Serbia's flagship biotechnology and life sciences hub, today announced the signing of a Memorandum of Understanding (MoU) to explore collaborative opportunities in biomedicine, biotechnology and bioinformatics, with a strong emphasis on AI applications.

In this blog, Elisa Petris, Partner at Syncona Investment Management Limited, and Emma Johnson, Senior Investment Manager – Life Sciences at the British Business Bank, write in their capacity as Co-founders of Invest in Equity. They share why they launched the initiative, the urgency of improving gender diversity in life science investment, and how a more inclusive ecosystem can drive stronger returns and better outcomes for patients.

Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company focused on drug development and delivery in diabetes and other cardiometabolic diseases, announces that it has concluded a positive Type C meeting with the US Food and Drug Administration (FDA) for AT278 in people with both type 1 and type 2 diabetes with high daily insulin needs.

Medicines Discovery Catapult (MDC) and King’s College London (KCL) have been awarded £400,000 funding from The Brain Tumour Charity to develop a groundbreaking new approach to treat glioblastoma, for patient benefit.

Brainomix, a global leader and pioneer of AI-powered imaging tools in stroke and lung fibrosis, has garnered widespread media attention1 this week following a renewed focus on the impact of its Brainomix 360 Stroke technology to improve recovery rates for stroke patients.

SeqOne, a pioneer in AI-driven genomic analysis, today announced it has entered into a definitive agreement to acquire Congenica, the UK company spun out of the prestigious Wellcome Sanger Institute.

Pioneer Group, a specialist in life science infrastructure and venture building, has launched a new Accelerator Programme for early-stage life science companies targeting unmet needs in the management of chronic conditions.

In this blog, Alastair Hall, Hub Eurasia Director, FI Group, explores how Innovate UK Innovation Loans are helping biotech SMEs bridge the gap between research and commercialisation. He highlights why they are most effective when combined with other funding sources to build a resilient strategy for growth.

BIA member Charm Therapeutics, co-founded by Nobel laureate David Baker, has raised an $80 million Series B to move its AI-designed cancer drug into the clinic early next year.

Roche’s Genentech unit has handed over $20 million in upfront cash for the license to Omass Therapeutics’ preclinical inflammatory bowel disease (IBD) program.

The fourth edition of the Tech Kickstarter Competition is now open for applications. If you are a seed or early-stage company working on a breakthrough product in life sciences, green tech, or tech/AI, this is your chance to accelerate your tech development.

Coulter Partners successfully completed a search assignment for AstriVax Therapeutics NV and is pleased to announce the placement of Dieter Weinand as Chair of its Board of Directors.

CancerTools.org, a unique non-profit cancer research tool supplier and part of Cancer Research UK, has chosen Discovery Park as the home of their first UK based laboratory, growing their team at the Sandwich Science and Tech campus.

The Cell and Gene Therapy Catapult (CGT Catapult) are absolutely delighted to share that it’s Skills Team has been recognised as one of the 57 exceptional training programmes to receive the prestigious Princess Royal Training Award this year for creating a future-ready workforce for advanced therapies!

Shaun Grady is becoming BIA chair, effective from January 2026, in another week of innovation for our sector.